Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Alyson Connor"'
Autor:
Tine A. Bækdal, Flemming L. Søndergaard, Morten Donsmark, Marie-Louise Hartoft-Nielsen, Alyson Connor
Publikováno v:
Clinical Pharmacology in Drug Development
Semaglutide, a glucagon‐like peptide‐1 (GLP‐1) analogue, has been coformulated in a tablet with the absorption enhancer, sodium N‐(8‐[2‐hydroxybenzoyl] amino) caprylate (SNAC). We investigated tablet erosion and the pharmacokinetics of or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::22737d91db0553ded98b50ed512b0c0e
https://doi.org/10.1002/cpdd.938
https://doi.org/10.1002/cpdd.938
Publikováno v:
Clinical Therapeutics. 40:1855-1867
Purpose ME-401 is a novel selective inhibitor of phosphatidylinositol 3 kinase p110δ, an enzyme often found overexpressed and overactive in B-cell malignancies. The current study was performed to assess the safety, tolerability, pharmacokinetics, an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77bd8de5c3e966fd3762dce89c2650ea
https://doi.org/10.1016/j.clinthera.2018.09.006
https://doi.org/10.1016/j.clinthera.2018.09.006
Autor:
Joseph K. Belanoff, Hazel Hunt, Pui Leung, Dan Combs, Alyson Connor, Kirsteen Donaldson, Vanessa Zann, Mark Strem, Suzanne Sweet
Publikováno v:
Clinical Pharmacology in Drug Development
CORT125134 is an orally active, high‐affinity, selective antagonist of the glucocorticoid receptor that is being developed for indications that may benefit from the modulation of cortisol activity. This first‐in‐human study was conducted to eva
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::468fb3c2060903268a1ed4a9ad8777c4
http://europepmc.org/articles/PMC5947602
http://europepmc.org/articles/PMC5947602
Autor:
John McDermott, Pranav Gupta, Philip Evans, Rajesh Krishna, Filippos Kesisoglou, Valerie Schulz, Ronald D. Smith, Evan J. Friedman, Patrick Larson, Matthew L. Rizk, Alyson Connor
Publikováno v:
Therapeutic innovationregulatory science. 50(6)
Raltegravir is an integrase strand transfer inhibitor indicated in combination with other anti-retroviral medicinal products for the treatment of HIV-1 infection, given twice daily. Although a BCS class II compound, raltegravir exhibits low colonic a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::781acbbf445ee39639074329ceda96ea
https://pubmed.ncbi.nlm.nih.gov/30231748
https://pubmed.ncbi.nlm.nih.gov/30231748
Autor:
Alyson Connor, Samir Anupam Shah, Wu Lin, Robert L. Berger, Pranav Gupta, David Monteith, John McDermott
Publikováno v:
Allergy and Asthma Proceedings. 36:48-57
Nasal deposition studies can demonstrate whether nasal sprays treating allergic rhinitis and polyposis reach the ciliated posterior nasal cavity, where turbinate inflammation and other pathology occurs. However, quantifying nasal deposition is challe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::435f4f9c9535088713f6e8c3ee95c45d
https://doi.org/10.2500/aap.2015.36.3817
https://doi.org/10.2500/aap.2015.36.3817
Publikováno v:
American Journal of Rhinology & Allergy. 28:117-121
Background Sensory attributes of intranasal corticosteroids, such as rundown to the back of the throat, may influence patient treatment preferences. This study compares the nasal deposition and nasal retention of a radiolabeled solution of ciclesonid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c20e60985459000070c6c85114c8c84c
https://doi.org/10.2500/ajra.2014.28.4026
https://doi.org/10.2500/ajra.2014.28.4026
Autor:
Alyson Connor, Yuji Matsui, Hikaru Sugihara, Akio Nishiura, Ian R. Wilding, Kazuya Abe, Hirofumi Takeuchi
Publikováno v:
European Journal of Pharmaceutical Sciences. 53:62-68
Pranlukast hydrate was demonstrated in a human site-of-absorption study to have extremely poor absorption properties in the lower gastrointestinal tract. The ratios of AUC0-24 in the distal small bowel and colon compared to stomach delivery were appr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e312518bb6cb4f66365b734e9a2352ee
https://doi.org/10.1016/j.ejps.2013.11.018
https://doi.org/10.1016/j.ejps.2013.11.018
Autor:
Jianing Zeng, Peter G. Ferrie, Randy C. Dockens, Ian R. Wilding, Robert Croop, Andrew B. Dennis, Alyson Connor, Peter Timmins, Sarah J. Nicholson
Publikováno v:
Biopharmaceutics & Drug Disposition. 33:522-535
Reducing the maximum plasma concentration whilst maintaining the exposure was shown to ameliorate adverse events following the oral administration of 6-hydroxybuspirone. This observation, along with a desire to provide for once daily dosing of this c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ce8ce899bda9ea69183bb95e6c713b93
https://doi.org/10.1002/bdd.1819
https://doi.org/10.1002/bdd.1819
Autor:
John McDermott, Lloyd Stevens, Ahmad Almaya, David C. Sperry, Evelyn D. Lobo, Alyson Connor, Mark D. Argentine
Publikováno v:
Pharmaceutical Research. 29:2912-2925
To optimize a controlled release (CR) matrix formulation with two goals: (1) effectively deliver a prodrug to a preferred absorption region of the upper GI tract, and (2) afford a PK profile similar to a "reference" CR formulation.A pharmacoscintigra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3bcf30676a3b961bc65ffbc914098b1
https://doi.org/10.1007/s11095-012-0798-1
https://doi.org/10.1007/s11095-012-0798-1
Autor:
Pamela McLawhon, Adrian J. Fretland, Peter N. Morcos, Micaela B. Reddy, Alyson Connor, Amy S. Zhou, Jonathan Q. Tran, Patrick F. Smith, Philip Evans, Barbara J. Brennan
Publikováno v:
Biopharmaceutics & Drug Disposition. 32:261-275
Danoprevir, a potent, selective inhibitor of HCV NS3/4A protease, has a short half-life in humans. Therefore, the feasibility of a controlled release (CR) formulation to allow less frequent dosing was investigated using experimental approaches and ph
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::86dd317d292a1495fb1b92be5de8de5a
https://doi.org/10.1002/bdd.756
https://doi.org/10.1002/bdd.756